Published in Ann Intern Med on February 01, 1987
The medically important aerobic actinomycetes: epidemiology and microbiology. Clin Microbiol Rev (1994) 7.26
Infections after liver transplantation. An analysis of 101 consecutive cases. Medicine (Baltimore) (1988) 5.77
Paracoccidioidomycosis: an update. Clin Microbiol Rev (1993) 3.12
Infections in solid-organ transplant recipients. Clin Microbiol Rev (1997) 2.86
Aspergillus infections in transplant recipients. Clin Microbiol Rev (2005) 2.82
The promoter-regulatory region of the major immediate-early gene of human cytomegalovirus responds to T-lymphocyte stimulation and contains functional cyclic AMP-response elements. J Virol (1989) 2.32
Emergence of new pathogens as a function of changes in host susceptibility. Emerg Infect Dis (1997) 1.21
In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus isolates from transplant and nontransplant patients. Antimicrob Agents Chemother (2004) 1.08
Antimicrobial strategies in the care of organ transplant recipients. Antimicrob Agents Chemother (1993) 1.01
Newer combination antifungal therapies for invasive aspergillosis. Med Mycol (2010) 1.01
A case of Aspergillus mediastinitis after heart transplantation successfully treated with liposomal amphotericin B, caspofungin and voriconazole. Eur J Clin Microbiol Infect Dis (2005) 0.90
Host defence to pulmonary mycosis. Can J Infect Dis (1999) 0.80
Characterization of the FKBP12-Encoding Genes in Aspergillus fumigatus. PLoS One (2015) 0.78
In vitro and in vivo activities of syn2836, syn2869, syn2903, and syn2921: new series of triazole antifungal agents. Antimicrob Agents Chemother (2001) 0.76
Five-years surveillance of invasive aspergillosis in a university hospital. BMC Infect Dis (2011) 0.76
Pentamidine in Pneumocystis jirovecii prophylaxis in heart transplant recipients. World J Transplant (2016) 0.75
Optimal regimens of sulfamethoxazole-trimethoprim for chemoprophylaxis of Pneumocystis pneumonia in patients with systemic rheumatic diseases: results from a non-blinded, randomized controlled trial. Arthritis Res Ther (2017) 0.75
Outcomes of Pneumocystis jiroveci pneumonia infections in pediatric heart transplant recipients. Pediatr Transplant (2011) 0.75
Successful management of sequential pulmonary infections in a cardiac transplant recipient. Can J Infect Dis (1990) 0.75
Decreased incidence of viral infections in liver transplant recipients. Possible effects of FK506? Dig Dis Sci (1994) 0.75
Life in the allogeneic environment after lung transplantation. Lung (1990) 0.75
Interferon-gamma: the major mediator of resistance against Toxoplasma gondii. Science (1988) 7.96
Toxoplasmic encephalitis in AIDS. Clin Infect Dis (1992) 7.64
Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts. N Engl J Med (1982) 6.79
An enzyme-linked immunosorbent assay for detection of IgM antibodies to Toxoplasma gondii: use for diagnosis of acute acquired toxoplasmosis. J Infect Dis (1980) 5.57
Failure to trigger the oxidative metabolic burst by normal macrophages: possible mechanism for survival of intracellular pathogens. J Exp Med (1980) 5.23
The biosynthesis of insulin and a probable precursor of insulin by a human islet cell adenoma. Proc Natl Acad Sci U S A (1967) 5.04
The compromised host and infection. II. Deep fungal infection. J Infect Dis (1969) 4.63
Heart-lung transplantation: successful therapy for patients with pulmonary vascular disease. N Engl J Med (1982) 4.40
Effect of normal and activated human macrophages on Toxoplasma gondii. J Exp Med (1974) 4.39
AIDS commentary. Toxoplasmic encephalitis. J Infect Dis (1988) 4.14
Toxoplasmosis in pregnancy. Clin Infect Dis (1994) 3.91
Direct agglutination test for diagnosis of Toxoplasma infection: method for increasing sensitivity and specificity. J Clin Microbiol (1980) 3.81
In vitro induction of nonspecific resistance in macrophages by specifically sensitized lymphocytes. Infect Immun (1971) 3.81
Control of carcinogenesis: a possible role for the activated macrophage. Science (1972) 3.69
Management of acute aortic dissections. Ann Thorac Surg (1970) 3.66
Interferon: protection of cells infected with an intracellular protozoan (Toxoplasma gondii). Science (1968) 3.65
Western Blot analysis of the antigens of Toxoplasma gondii recognized by human IgM and IgG antibodies. J Immunol (1983) 3.53
Toxoplasmic encephalitis in patients with acquired immune deficiency syndrome. JAMA (1984) 3.48
Minimally invasive coronary artery surgery--a word of caution. J Thorac Cardiovasc Surg (1997) 3.37
Studies on the mechanisms of resistance to phylogenetically diverse intracellular organisms. J Immunol (1969) 3.29
Development of adverse sequelae in children born with subclinical congenital Toxoplasma infection. Pediatrics (1980) 3.21
Importance of endogenous IFN-gamma for prevention of toxoplasmic encephalitis in mice. J Immunol (1989) 3.20
A role for activated macrophages in resistance to infection with Toxoplasma. Infect Immun (1972) 3.12
IgM antibodies in acute toxoplasmosis. II. Prevalence and significance in acquired cases. J Lab Clin Med (1968) 3.07
Association of CD4+ T cell-dependent, interferon-gamma-mediated necrosis of the small intestine with genetic susceptibility of mice to peroral infection with Toxoplasma gondii. J Exp Med (1996) 2.97
Toxoplasmosis in the compromised host. Ann Intern Med (1976) 2.96
Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. JAMA (1989) 2.87
False-positive results in immunoglobulin M (IgM) toxoplasma antibody tests and importance of confirmatory testing: the Platelia Toxo IgM test. J Clin Microbiol (1997) 2.84
Induction of resistance to Toxoplasma gondii in human macrophages by soluble lymphocyte products. J Immunol (1976) 2.79
Dual regulation of resistance against Toxoplasma gondii infection by Lyt-2+ and Lyt-1+, L3T4+ T cells in mice. J Immunol (1988) 2.77
Effect of testing for IgG avidity in the diagnosis of Toxoplasma gondii infection in pregnant women: experience in a US reference laboratory. J Infect Dis (2001) 2.74
Phagocytic and bacterial properties of normal human monocytes. J Clin Invest (1974) 2.65
Heart and combined heart-kidney transplantation in patients with concomitant renal insufficiency and end-stage heart failure. Am J Transplant (2013) 2.61
Immunoglobulin M-immunosorbent agglutination assay for diagnosis of infectious diseases: diagnosis of acute congenital and acquired Toxoplasma infections. J Clin Microbiol (1981) 2.61
Resistance to murine tumors conferred by chronic infection with intracellular protozoa, Toxoplasma gondii and Besnoitia jellisoni. J Infect Dis (1971) 2.58
Remarkable in vitro and in vivo activities of the hydroxynaphthoquinone 566C80 against tachyzoites and tissue cysts of Toxoplasma gondii. Antimicrob Agents Chemother (1991) 2.56
Toxoplasmosis: the time has come. N Engl J Med (1988) 2.54
Activity of recombinant tumor necrosis factor on Toxoplasma gondii and Trypanosoma cruzi. J Immunol (1986) 2.53
IgA antibodies for diagnosis of acute congenital and acquired toxoplasmosis. J Infect Dis (1990) 2.49
Production of gamma interferon by natural killer cells from Toxoplasma gondii-infected SCID mice: regulation by interleukin-10, interleukin-12, and tumor necrosis factor alpha. Infect Immun (1994) 2.48
The effect of anti-IFN-gamma antibody on the protective effect of Lyt-2+ immune T cells against toxoplasmosis in mice. J Immunol (1990) 2.47
The use of killed vaccines in immunization against an intracellular parasite: Toxoplasma gondii. J Immunol (1972) 2.46
Toxoplasmosis acquired during pregnancy: improved serodiagnosis based on avidity of IgG. J Infect Dis (1993) 2.45
Possible role of macrophage mediated nonspecific cytotoxicity in tumour resistance. Nat New Biol (1972) 2.44
Detection and characterization of membrane antigens of Toxoplasma gondii. J Immunol (1980) 2.43
Prosthetic replacement of the aortic arch. J Thorac Cardiovasc Surg (1975) 2.43
Serious adverse events of mefloquine in relation to blood level and gender. Am J Trop Med Hyg (2001) 2.41
The cardiac donor. Surg Gynecol Obstet (1971) 2.39
Infectious complications after cardiac transplantation in man. Ann Intern Med (1971) 2.37
IgM antibodies in acute toxoplasmosis. I. Diagnostic significance in congenital cases and a method for their rapid demonstration. Pediatrics (1968) 2.36
Resistance against Cryptococcus conferred by intracellular bacteria and protozoa. J Infect Dis (1971) 2.34
The etiologic spectrum of constrictive pericarditis. Am Heart J (1987) 2.34
Sensitivity and specificity of echocardiographic diagnosis of pericardial effusion. Circulation (1974) 2.28
Effect of murine interferon gamma on murine toxoplasmosis. J Infect Dis (1984) 2.27
Cardiac transplantation in perspective for the future. Survival, complications, rehabilitation, and cost. J Thorac Cardiovasc Surg (1982) 2.26
A human T lymphocyte differentiation marker defined by monoclonal antibodies that block E-rosette formation. J Immunol (1981) 2.20
Antigenemia in recently acquired acute toxoplasmosis. J Infect Dis (1980) 2.20
Differential agglutination test for diagnosis of recently acquired infection with Toxoplasma gondii. J Clin Microbiol (1990) 2.19
Azithromycin, a macrolide antibiotic with potent activity against Toxoplasma gondii. Antimicrob Agents Chemother (1988) 2.16
Value of lymph-node biopsy in the diagnosis of acute acquired toxoplasmosis. N Engl J Med (1973) 2.15
Effect of clindamycin on acute and chronic toxoplasmosis in mice. Antimicrob Agents Chemother (1974) 2.14
Gamma-M-fluorescent treponemal antibody in the diagnosis of congenital syphilis. N Engl J Med (1969) 2.10
Infectious complications among 620 consecutive heart transplant patients at Stanford University Medical Center. Clin Infect Dis (2001) 2.09
Toxoplasmosis in the adult--an overview. N Engl J Med (1978) 2.06
Intracoronary ultrasound in cardiac transplant recipients. In vivo evidence of "angiographically silent" intimal thickening. Circulation (1992) 2.04
Toxoplasmic chorioretinitis in the setting of acute acquired toxoplasmosis. Clin Infect Dis (1996) 2.04
IgM enzyme-linked immunosorbent assay test for the diagnosis of congenital Toxoplasma infection. J Pediatr (1981) 2.04
Evaluation of the effect of drugs on the cyst form of Toxoplasma gondii. J Infect Dis (1991) 2.04
Nocardial infections in the immunocompromised host: A detailed study in a defined population. Rev Infect Dis (1981) 2.03
Method for avoiding false-positive results occurring in immunoglobulin M enzyme-linked immunosorbent assays due to presence of both rheumatoid factor and antinuclear antibodies. J Clin Microbiol (1981) 2.03
Effect of intrathoracic pressure on left ventricular performance. N Engl J Med (1979) 2.01
Surgical management of primary aortoesophageal fistula secondary to thoracic aneurysm. Ann Thorac Surg (2000) 2.01
Tropical fish aquariums. A source of Mycobacterium marinum infections resembling sporotrichosis. JAMA (1970) 2.00
In vivo recombinant interleukin 2 administration enhances survival against a lethal challenge with Toxoplasma gondii. J Immunol (1985) 2.00
Serologic diagnosis of acute lymphadenopathic toxoplasmosis. J Infect Dis (1980) 1.99
Rapid prenatal diagnosis of congenital Toxoplasma infection by using polymerase chain reaction and amniotic fluid. J Clin Microbiol (1990) 1.95
Dissociation of effector functions in populations of activated macrophages. Nature (1977) 1.95
Analysis of Toxoplasma gondii antigens recognized by human sera obtained before and after acute infection. J Infect Dis (1986) 1.93
The RNA of toxoplasma gondii. Proc Soc Exp Biol Med (1970) 1.93
Synthetic polyanions protect mice against intracellular bacterial infection. Nature (1970) 1.92
Post-transplant obliterative bronchiolitis and other late lung sequelae in human heart-lung transplantation. Chest (1984) 1.91
Genetic control of murine resistance to Toxoplasma gondii. Infect Immun (1978) 1.91
Multiple valve replacement with the fresh aortic homograft. J Thorac Cardiovasc Surg (1968) 1.90
Immunity and intracellular infection: resistance to bacteria in mice infected with a protozoan. Science (1968) 1.88
Treatment of patients with aortic dissection presenting with peripheral vascular complications. Ann Surg (1990) 1.88
Idiopathic cardiomyopathy, age, and suppressor-cell dysfunction as risk determinants of lymphoma after cardiac transplantation. Lancet (1978) 1.87
A method to evaluate the capacity of monocytes and macrophages to inhibit multiplication of an intracellular pathogen. J Immunol Methods (1979) 1.87
Evaluation of new anti-infective drugs for the treatment of respiratory tract infections. Infectious Diseases Society of America and the Food and Drug Administration. Clin Infect Dis (1992) 1.86
Opportunistic invasive fungal infections in patients with leukaemia lymphoma. Clin Haematol (1976) 1.86
Evaluation of six commercial kits for detection of human immunoglobulin M antibodies to Toxoplasma gondii. The FDA Toxoplasmosis Ad Hoc Working Group. J Clin Microbiol (1997) 1.85